<div><p><b>Background: </b>Cirrhosis is characterised by severe liver fibrosis, organ dysfunction and liver-related complications. Presently, there are no approved anti-fibrotic or pro-regenerative therapies for cirrhosis. Preclinical studies have shown bone marrow-derived macrophage injections can resolve hepatic fibrosis, stimulate regeneration and reduce inflammation.

<div><p><b>Background: </b>To evaluate the impact of CT-based deep learning model of hepatic venous pressure gradient (HVPG) on prognosis of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE) and systemic therapy.</p>

<div><p><b><span data-contrast="auto">Background</span></b><span data-contrast="auto">: The “French Medicine Genomic program 2025” is an academic research program that allows to perform whole-genome/exome/RNA sequencing in advanced cancer refractory to systemic treatments to give access to off-labeled therapies adapted to genomic alterations in clinical practice. We reported results in intermediate and advanced hepatocellular carcinoma (HCC) and hepato-cholangiocarcinoma (H-CCK).

<div><p><b>Background:</p> </b><p style="font-weight: 400;">This study was performed to examine the effect of empagliflozin on liver fat content in T2DM patients and in nondiabetic individuals, and the relationship between the decrease in liver fat and other metabolic actions of empagliflozin.</p>

<div><p><b>Background: </b>FDA recommended histopathological end-points for NASH clinical trials may not be fully evaluated by conventional histological staging. Shorter time frames in NASH trials make it difficult to assess changes in treatment-induced fibrosis with current classification systems. Assessment of specific morphological fibrosis parameters and their quantification in specific zones of NASH-CRN classification, can be done by SHG/TPE-based AI platforms.

<div><p><b>Background: </b>Alagille syndrome (ALGS) is a rare, genetic, multisystem disorder in which cholestatic liver disease is common and that may include clinical manifestations of severe pruritus and elevated bile acids (BAs). The efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor, were assessed in patients with ALGS in the phase 3 ASSERT and ASSERT-EXT trials. Using data from these studies, we analyzed the effects of odevixibat on pruritus and BAs over time.</p>

<div><p><b>Background:</p> </b><p>Chronic inflammation due to various etiologies leads to liver fibrosis and subsequently cirrhosis. The liver lymphatic system helps to reduce inflammation. We hypothesized that the liver lymphatic system ameliorates liver fibrosis/cirrhosis.</p>

<div><p><b>Background: </b>We reported the HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg/HBcAg mixed with mucoadhesive excipient carboxy-vinyl polymer (CVP-NASVAC) in chronically HBV infected patients. This study was aimed to assess the long-term efficacy of CVP-NASVAC at 48 months after the first 10 doses.</p>

<div><p><b>Background: </b>About 30% of patients with PBC have a suboptimal response to ursodeoxycholic acid (UDCA), leading to a worse prognosis. In the phase III POISE trial, response to obeticholic acid (OCA) was assessed by using the POISE score. Recently, complete biochemical normalization (normal ALP and bilirubin ≤ 0.6 ULN) has been proposed as a new therapeutic aim in PBC, as it significantly improves liver-related and overall survival, but the effectiveness of second-line therapy for this new therapeutic target has not been evaluated.</p>

<div><p><b>Background:<span> </b>Patients with cirrhosis have increased surgical risk compared to the general population. Preoperative optimization by nonsurgical clinicians improves postoperative outcomes after colectomy in studies of patients with major comorbidities, however, data specific to patients with cirrhosis and addressing more diverse surgeries are limited.